Among cancers that affect men, prostate cancer is the most common and carries the second highest rate of mortality. How does diet play a role in this widespread public health concern, which affects 11.6% of American men at some time in their lives? A new literature review published in The Journal of the American Osteopathic Association reports that consuming high amounts of dairy may increase prostate cancer risk, while consuming high amounts of plant-based foods may decrease risk. "Previous stu...
Researchers recently discovered that cabazitaxel, compared with abiraterone or enzalutamide, is a potentially more effective drug to use in the fight against metastatic castration-resistant prostate cancer. Androgen-deprivation therapy (ADT), such as abiraterone or enzalutamide, hinders the body from producing testosterone, which fuels prostate cancer cells. However, resistance often occurs when this type of therapy is used. Cabazitaxel, an anti-microtubule chemotherapy drug, works by inhibiting...
On September 17, 2019, the FDA approved apalutamide (Erleada®, Janssen Biotech, Inc.) in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (CSPC). The approval was based on TITAN (NCT02489318), a Phase III clinical trial led by Kim N. Chi, MD, Vice President of BC Cancer Agency in Vancouver and Professor of Medicine at the University of British Columbia. In this interview with i3 Health, Dr. Chi discusses the significance of the...
A phase 3 trial reports that stereotactic body radiotherapy (SBRT), which takes significantly less time than standard-of-care intensity-modulated fractionated radiotherapy (IMRT), is equally safe for patients with prostate cancer. The international, open-label PACE-B trial (NCT01584258) randomized 874 men with low- or intermediate-risk prostate adenocarcinoma in a 1:1 ratio to receive either SBRT (36.25 Gy) in five fractions over one to two weeks, or conventionally fractionated or moderately h...
The FDA has approved apalutamide (Erleada®, Janssen Biotech, Inc.) in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (CSPC). The approval was based on TITAN (NCT02489318), a randomized, double-blind, placebo-controlled, multicenter clinical trial that enrolled 1,052 patients with metastatic CSPC, including patients with both high- and low-volume disease. Prior treatment for localized disease and prior docetaxel therapy were a...